Schizophrenia Research
Volume 77, Issue 1 , Pages 35-41 , 1 September 2005

Increased prevalence of schizophrenia spectrum disorders in relatives of neuroleptic-nonresponsive schizophrenic patients

  • Ridha Joober

      Affiliations

    • Douglas Hospital Research Center, Douglas Hospital, Verdun, Quebec, Canada
    • ,
  • Guy A. Rouleau

      Affiliations

    • Montreal General Research Institute, Montreal General Hospital, Montreal, Quebec, Canada
    • ,
  • Samarthji Lal

      Affiliations

    • Douglas Hospital Research Center, Douglas Hospital, Verdun, Quebec, Canada
    • ,
  • David Bloom

      Affiliations

    • Douglas Hospital Research Center, Douglas Hospital, Verdun, Quebec, Canada
    • ,
  • Pierre Lalonde

      Affiliations

    • L.H. Lafontaine Hospital, Université de Montréal, Montreal, Canada
    • ,
  • Alain Labelle

      Affiliations

    • Royal Ottawa Hospital, University of Ottawa, Ottawa, Canada
    • ,
  • Chawki Benkelfat

      Affiliations

    • Allan Memorial Institute, Department of Psychiatry, McGill University, 1033, Pine Avenue W, Montreal, Quebec, Canada, H3A 1A1
    • Corresponding Author InformationCorresponding author.

Received 7 June 2004 ,Revised 14 January 2005 ,Accepted 18 January 2005.

References 

  1. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr. Bull. 1990;16:551–561
  2. Cooper TB. Neuroleptic responsive versus resistant patients. Contemporary issues in the treatment of schizophrenia. Washington, DC: American Psychiatric Press; 1995;
  3. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch. Gen. Psychiatry. 1976;33:766–771
  4. Galdi J, Rieder RO, Silber D, Bonato RR. Genetic factors in the response to neuroleptics in schizophrenia: a psychopharmacogenetic study. Psychol. Med. 1981;11:713–728
  5. Garver DL, Kelly K, Fried KA, Magnusson M, Hirschowitz J. Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol. Med. 1988;18:873–885
  6. Joober R, Rouleau GA, Lal S, Dixon M, O'Driscoll G, Palmour R, et al. Neuropsychological impairments in neuroleptic-responder vs. -nonresponder schizophrenic patients and healthy volunteers. Schizophr. Res. 2002;53:229–238
  7. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 1988;45:789–796
  8. Maxwell E. Family interview for genetic studies. NIMH. 1992;(Ref type: serial (Book, Monograph))
  9. McGue M, Gottesman II, Rao DC. The transmission of schizophrenia under a multifactorial threshold model. Am. J. Hum. Genet. 1983;35:1161–1178
  10. Miller CD. Nam–Pwers Scale. In:  Miller CD editors. Handbook of research design and social measurement. Newbury Park, CA: Sage Publications; 1991;
  11. Roy MA, Walsh D, Kendler KS. Accuracies and inaccuracies of the family history method: a multivariate approach. Acta Psychiatr. Scand. 1996;93:224–234
  12. Silverman JM, Mohs RC, Davidson M, Losonczy MF, Keefe RS, Breitner JC, et al. Familial schizophrenia and treatment response. Am. J. Psychiatry. 1987;144:1271–1276
  13. Verdoux H, van OJ, Sham P, Jones P, Gilvarry K, Murray R. Does familiality predispose to both emergence and persistence of psychosis? A follow-up study. Br. J. Psychiatry. 1996;168:620–626
  14. Wolkin A, Barouche F, Wolf AP, Rotrosen J, Fowler JS, Shiue CY, et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. Am. J. Psychiatry. 1989;146:905–908

☆ Presented in part as an oral presentation at the Society of Biological Psychiatry Annual Meeting, Washington D.C., May 13-15, 1999.

PII: S0920-9964(05)00047-2

doi: 10.1016/j.schres.2005.01.008

Schizophrenia Research
Volume 77, Issue 1 , Pages 35-41 , 1 September 2005

Article Tools